Aprepitant and control of emesis induced by five-day chemotherapy
Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving five-day cisplatin-containing chemotherapy, a new trial shows. Some needs in antiemetic therapy remain [more]